The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col
The model's full reasoning — Q3 2017 call → NOWe need answer YES/NO based on transcript. Need determine if management conveys recently finished expensive/uncertain/heavy phase of major undertaking and now collecting phase with reported results still reflecting paying phase. Let's parse transcript. Key topics: MiFID II preparations. Management says: "Our preparations for MiFID II are on schedule and we have reached multiple milestones..." "MarketAxess [indiscernible] tracks has been granted approval by U.K. FCA to operate as an APA... ARM. MarketAxess results recently approved by MAS to operate as RMO... We expect MiFID II reporting, transparency, and best execution obligations to drive greater demand for electronic trading and market data solutions. We have made significant investments in all three areas to help clients with upcoming regulatory changes." Also expenses: "Operating expenses up 13% due to ongoing investments and expenses related to global regulatory changes." Tony: "We are occurring additional expenses this year... majority of uplift in professional consulting had to do with planning on MiFID II embraced it and establishing new trading venues... chunk will recur... Other piece technology related... around $4.5 million this year... has been capitalized once MiFID II goes live, we will start amortizing those costs over three years... you will see increase in expenses like that." So not finished; still investing, regulatory changes upcoming. "preparations on schedule" but not done; MiFID II implementation in future. No indication heavy phase completed; rather they expect MiFID II to drive demand, but benefit hasn't arrived yet. They mention "We expect" future benefits. So likely NO. Another possible undertaking: Open Trading? They discuss growth, record, but not heavy phase completed. High-yield fee plan? Implemented August 1, but not expensive heavy phase. International expansion? Ongoing. BondPoint? They declined acquisition; no. Question asks: "Does management convey that company has RECENTLY FINISHED THE EXPENSIVE, UNCERTAIN, OR HEAVY PHASE OF A MAJOR UNDERTAKING ... and has now entered the phase where company COLLECTS on that completed work, with reported results still mostly reflecting paying phase rather than collecting phase?" Need both halves. MiFID II: expenses related to regulatory changes are ongoing, some capitalized and will be amortized after go-live.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| CURV | Torrid Holdings Inc. | Q2 2022 | 2022-09-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ARCB | ArcBest Corporation | Q4 2016 | 2017-02-08 | C |
IONS · Q1 2017 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the heavy phase of the SPINRAZA program as concluded ("we concluded our costly Phase III program"), with R&D expenses now expected to decline as the company transitions to a multiproduct profitable organization. They note that Q1 marked the first full quarter of commercial revenues ($47 million), with royalties of 5.2 million reflecting the early stage of this new revenue stream, while the reported results still include substantial R&D revenue (102 million) and show profitability driven by the ongoing evolution toward sustained profitability. The commercial benefits are visibly beginning but remain early, with the numbers carrying the burden of the prior development effort.
PKOH · Q3 2022 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where they collect...YES Management describes the restructuring of 14 global locations as "largely completed," with the cycle finished and no significant customer attrition. They are now pivoting to focus on the balance sheet and "harvesting some of the significant cash investments" made over the last couple of years, while noting that earnings are continuing to improve sequentially in Q4 despite inflation. The reported results show positive cash flow and improved metrics, but the harvest is described as beginning, with the $60 million working capital investment expected to convert over 12-18 months, indicating the collecting phase is early and the numbers still largely reflect the prior paying phase.
AKYA · Q2 2023 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the first phase (2021–end of 2022) as having completed its core objectives: successful launch of Fusion, portfolio development, organizational expansion, and platform enhancements. They explicitly frame the second phase as now beginning, with the reported Q2 results still carrying the burden of that prior heavy investment (high OpEx, RIF charges, gross-margin pressure) while the new phase is visibly starting to deliver through record revenue, reagent pull-through, and cost-optimization moves. The numbers lag the crossing, as the company is still pre-profitability and targeting cash-flow positivity only in 2025.